• Vinayak Kohli
    Vinayak Kohli
    • over 7 years ago
    • Practical Guidance Journal
    • pa

    In-House Counsel’s Role In Cybersecurity & Data Protection

    THE CONDUCTOR CANNOT HOPE TO KNOW EVERYTHING about each section of the orchestra, (e.g., what strings, woodwinds, brass, and percussion must do in order to play their part). However, each section (and subsection) has its own chair who can determine that...
  • Vinayak Kohli
    Vinayak Kohli
    • over 8 years ago
    • Practical Guidance Journal
    • pa

    Strategies and Opportunities in an America Invents Act World – Choices of Venue

    By: Ethan Horwitz , Carlton Fields. TODAY, BOTH PATENT OWNERS AND ACCUSED INFRINGERS have multiple choices of venues in which to litigate the validity of a patent. There is the historic option of a patent infringement case in the federal courts. Increasingly...
  • Vinayak Kohli
    Vinayak Kohli
    • over 7 years ago
    • Practical Guidance Journal
    • pa

    Preparing for Random Trademark Registration Audits

    By: Janet Marvel Pattishall, Mcauliffe, Newbury, Hilliard & Geraldson LLP The U.S. Patent and Trademark Office (USPTO) is commencing random audits of trademark registrations in which Declarations of Use have been filed to verify that the registered...
  • Vinayak Kohli
    Vinayak Kohli
    • over 7 years ago
    • Practical Guidance Journal
    • pa

    Biometric Information Protection: The Stage is Set for Expansion of Claims

    By: Torsten M. Kracht, Michael J. Mueller, Lisa J. Sotto, and Daniella Sterns Hunton & Williams LLP Litigation alleging the improper collection and storage of biometric data is being driven by the Illinois Biometric Information Protection Act (BIPA...
  • Vinayak Kohli
    Vinayak Kohli
    • over 6 years ago
    • Practical Guidance Journal
    • pa

    Biosimilars and The Biologics Price Competition and Innovation Act (BPCIA)

    By: Michael Furrow , DLA Piper, and Whitney Meier , Venable LLP The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated pathway for companies to bring biologic drugs to market that are biosimilar to previously approved branded...
<>